Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.

Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik VI, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst HA, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih HR, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H.

Leukemia. 2018 Apr 17. doi: 10.1038/s41375-018-0129-6. [Epub ahead of print]

PMID:
29720733
2.

Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.

Wais V, Kündgen L, Bohl SR, von Harsdorf S, Schlenk RF, Döhner K, Teleanu V, Bullinger L, Nguyen TM, Drognitz K, Moulin JC, Binnenhei M, Bentz M, Döhner H, Bunjes D, Kuchenbauer F, Ringhoffer M.

Bone Marrow Transplant. 2018 Jan;53(1):94-96. doi: 10.1038/bmt.2017.211. Epub 2017 Nov 13. No abstract available.

PMID:
29131153
3.

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.

Gaidzik VI, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, Krönke J, Kapp-Schwoerer S, Krämer D, Horst HA, Schmidt-Wolf I, Held G, Kündgen A, Ringhoffer M, Götze K, Kindler T, Fiedler W, Wattad M, Schlenk RF, Bullinger L, Teleanu V, Schlegelberger B, Thol F, Heuser M, Ganser A, Döhner H, Döhner K; German-Austrian Acute Myeloid Leukemia Study Group (AMLSG).

Leukemia. 2018 Jan;32(1):30-37. doi: 10.1038/leu.2017.200. Epub 2017 Jun 23.

PMID:
28643785
4.

Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma.

Knop S, Langer C, Engelhardt M, Mügge LO, Reichle A, Rösler W, Bassermann F, Hertenstein B, Kunitz A, Röllig C, Ostermann H, Schäfer-Eckart K, Ringhoffer M, Günther A, Junghanss C, Biersack H, Schreder M, Liebert A, Held S, Einsele H, Bargou RC.

Leukemia. 2017 Aug;31(8):1816-1819. doi: 10.1038/leu.2017.124. Epub 2017 Apr 25. No abstract available.

PMID:
28439106
5.

Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

Wattad M, Weber D, Döhner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, Thol F, Kindler T, Lübbert M, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Köhne CH, Ringhoffer M, Wulf G, Held G, Salwender H, Benner A, Ganser A, Döhner H, Schlenk RF.

Leukemia. 2017 Jun;31(6):1306-1313. doi: 10.1038/leu.2017.23. Epub 2017 Jan 19.

PMID:
28138160
6.

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.

Schlenk RF, Frech P, Weber D, Brossart P, Horst HA, Kraemer D, Held G, Ringhoffer M, Burchardt A, Kobbe G, Götze K, Nachbaur D, Fischer T, Lübbert M, Salih HR, Salwender H, Wulf G, Koller E, Wattad M, Fiedler W, Kremers S, Kirchen H, Hertenstein B, Paschka P, Gaidzik VI, Teleanu V, Heuser M, Thol F, Döhner K, Krauter J, Ganser A, Döhner H; the German-Austrian AMLSG.

Leukemia. 2017 May;31(5):1217-1220. doi: 10.1038/leu.2017.22. Epub 2017 Jan 18. No abstract available.

7.

Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation.

Fuerst D, Neuchel C, Niederwieser D, Bunjes D, Gramatzki M, Wagner E, Wulf G, Glass B, Pfreundschuh M, Einsele H, Arnold R, Stuhler G, Schaefer-Eckart K, Freitag S, Casper J, Kaufmann M, Wattad M, Hertenstein B, Klein S, Ringhoffer M, Mytilineos D, Tsamadou C, Mueller C, Schrezenmeier H, Mytilineos J.

Blood. 2016 Dec 29;128(26):3169-3176. doi: 10.1182/blood-2016-05-716357. Epub 2016 Nov 3.

8.

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk RF, Döhner K, Döhner H.

Leukemia. 2016 Nov;30(11):2282. doi: 10.1038/leu.2016.207. No abstract available.

PMID:
27804971
9.

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

Theis F, Corbacioglu A, Gaidzik VI, Paschka P, Weber D, Bullinger L, Heuser M, Ganser A, Thol F, Schlegelberger B, Göhring G, Köhne CH, Germing U, Brossart P, Horst HA, Haase D, Götze K, Ringhoffer M, Fiedler W, Nachbaur D, Kindler T, Held G, Lübbert M, Wattad M, Salih HR, Krauter J, Döhner H, Schlenk RF, Döhner K.

Leukemia. 2016 Nov;30(11):2248-2250. doi: 10.1038/leu.2016.185. Epub 2016 Jul 4. No abstract available.

PMID:
27375010
10.

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk RF, Döhner K, Döhner H.

Leukemia. 2016 Nov;30(11):2160-2168. doi: 10.1038/leu.2016.126. Epub 2016 May 3. Erratum in: Leukemia. 2016 Nov;30(11):2282.

PMID:
27137476
11.

Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas.

van Gorkom G, Finel H, Giebel S, Pohlreich D, Shimoni A, Ringhoffer M, Sucak G, Schaap N, Dreger P, Sureda A, Schouten HC.

J Clin Apher. 2017 Oct;32(5):295-301. doi: 10.1002/jca.21506. Epub 2016 Sep 10.

PMID:
27614935
12.

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT.

Bohl S, von Harsdorf S, Mulaw M, Hofmann S, Babiak A, Maier CP, Schnell J, Hütter-Krönke LM, Scholl K, Wais V, Schlenk RF, Bullinger L, Ringhoffer M, Döhner H, Bunjes D, Bommer M, Kuchenbauer F.

Bone Marrow Transplant. 2016 Jul;51(7):994-6. doi: 10.1038/bmt.2016.4. Epub 2016 Mar 7. No abstract available.

13.

Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party.

Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger LA, Oechsle K, Schumacher K, Kanfer E, Bourhis JH, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F.

Bone Marrow Transplant. 2016 Mar;51(3):384-90. doi: 10.1038/bmt.2015.300. Epub 2015 Dec 7.

PMID:
26642334
14.

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.

Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne CH, Brossart P, Held G, Horst HA, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K.

Haematologica. 2015 Mar;100(3):324-30. doi: 10.3324/haematol.2014.114157. Epub 2015 Jan 16.

15.

Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.

Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK, Wolf D, Ringhoffer M, Czibere A, Nachtkamp K, Dienst A, Kondakci M, Stadler M, Platzbecker U, Uharek L, Luft T, Fenk R, Germing U, Bornhäuser M, Kröger N, Beelen DW, Haas R, Kobbe G.

Biol Blood Marrow Transplant. 2015 Apr;21(4):653-60. doi: 10.1016/j.bbmt.2014.12.016. Epub 2014 Dec 23.

16.

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G, Brossart P, Lübbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, Götze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Späth D, Benner A, Krauter J, Ganser A, Döhner H, Döhner K; German-Austrian AML Study Group.

Blood. 2014 Nov 27;124(23):3441-9. doi: 10.1182/blood-2014-05-578070. Epub 2014 Sep 30.

17.

Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.

Tassara M, Döhner K, Brossart P, Held G, Götze K, Horst HA, Ringhoffer M, Köhne CH, Kremers S, Raghavachar A, Wulf G, Kirchen H, Nachbaur D, Derigs HG, Wattad M, Koller E, Brugger W, Matzdorff A, Greil R, Heil G, Paschka P, Gaidzik VI, Göttlicher M, Döhner H, Schlenk RF.

Blood. 2014 Jun 26;123(26):4027-36. doi: 10.1182/blood-2013-12-546283. Epub 2014 May 5. Erratum in: Blood. 2015 May 7;125(19):3037.

18.

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).

Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brugger W, Derigs HG, Kremers S, Greil R, Raghavachar A, Ringhoffer M, Salih HR, Wattad M, Kirchen HG, Runde V, Heil G, Petzer AL, Girschikofsky M, Heuser M, Kayser S, Goehring G, Teleanu MV, Schlegelberger B, Ganser A, Krauter J, Bullinger L, Döhner H, Döhner K.

Blood. 2013 Jun 6;121(23):4769-77. doi: 10.1182/blood-2012-10-461624. Epub 2013 Apr 30.

19.

T-cell reconstitution after allogeneic stem cell transplantation: assessment by measurement of the sjTREC/βTREC ratio and thymic naive T cells.

Ringhoffer S, Rojewski M, Döhner H, Bunjes D, Ringhoffer M.

Haematologica. 2013 Oct;98(10):1600-8. doi: 10.3324/haematol.2012.072264. Epub 2013 Apr 12.

20.

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation.

Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, Elter T, von Bubnoff N, Dreyling M, Ringhoffer M, Krause SW, Derigs G, Klimm B, Niemann D, Fritsch K, Finke J, Illerhaus G.

Haematologica. 2013 May;98(5):765-70. doi: 10.3324/haematol.2012.076075. Epub 2013 Jan 8.

21.

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).

Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Späth D, Kayser S, Schlegelberger B, Krauter J, Ganser A, Köhne CH, Held G, von Lilienfeld-Toal M, Kirchen H, Rummel M, Götze K, Horst HA, Ringhoffer M, Lübbert M, Wattad M, Salih HR, Kündgen A, Döhner H, Döhner K.

Blood. 2013 Jan 3;121(1):170-7. doi: 10.1182/blood-2012-05-431486. Epub 2012 Oct 31.

22.

Cerebrospinal fluid pleocytosis: pitfalls and benefits of combined analysis using cytomorphology and flow cytometry.

Bommer M, Nagy A, Schöpflin C, Pauls S, Ringhoffer M, Schmid M.

Cancer Cytopathol. 2011 Feb 25;119(1):20-6. doi: 10.1002/cncy.20127. Epub 2011 Jan 24.

23.

Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation.

Schmitt A, Tonn T, Busch DH, Grigoleit GU, Einsele H, Odendahl M, Germeroth L, Ringhoffer M, Ringhoffer S, Wiesneth M, Greiner J, Michel D, Mertens T, Rojewski M, Marx M, von Harsdorf S, Döhner H, Seifried E, Bunjes D, Schmitt M.

Transfusion. 2011 Mar;51(3):591-9. doi: 10.1111/j.1537-2995.2010.02940.x. Epub 2010 Dec 6.

PMID:
21133926
24.

Neoplastic meningitis in patients with acute myeloid leukemia scheduled for allogeneic hematopoietic stem cell transplantation.

Bommer M, von Harsdorf S, Döhner H, Bunjes D, Ringhoffer M.

Haematologica. 2010 Nov;95(11):1969-72. doi: 10.3324/haematol.2010.025999. Epub 2010 Jul 27.

25.

Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancer.

Greiner J, Küfer R, Reske SN, Martin V, Döhner H, Ringhoffer M.

Case Rep Med. 2010;2010:395720. doi: 10.1155/2010/395720. Epub 2010 Apr 11.

26.

High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.

Greiner J, Schmitt A, Giannopoulos K, Rojewski MT, Götz M, Funk I, Ringhoffer M, Bunjes D, Hofmann S, Ritter G, Döhner H, Schmitt M.

Haematologica. 2010 Jul;95(7):1191-7. doi: 10.3324/haematol.2009.014704. Epub 2010 Jan 15.

27.

[Prevention, early diagnosis and treatment of chemoextravasation. Practical management in the uro-oncological practice].

Rinnab L, Ringhoffer M, Mayer-Steinacker R, Hautmann RE, Simon J.

Urologe A. 2009 Nov;48(11):1283-4, 1286-90, 1292-4. doi: 10.1007/s00120-009-2103-4. Review. German.

PMID:
19888614
28.

[Systemic therapy of metastatic renal cell carcinoma: from many options to the therapeutic strategy].

Ringhoffer M, Rinnab L, Küfer R, Greiner J.

Urologe A. 2009 Nov;48(11):1308-17. doi: 10.1007/s00120-009-2109-y. Review. German.

PMID:
19806342
29.

RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.

Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L, Rubin MA, Greiner J, Schmitt M, Kuefer R, Ringhoffer M.

Neoplasia. 2009 Sep;11(9):956-63.

30.

Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling.

Chen J, Schmitt A, Chen B, Rojewski M, Rübeler V, Fei F, Yu Y, Yu X, Ringhoffer M, von Harsdorf S, Greiner J, Götzz M, Guillaume P, Döhner H, Bunjes D, Schmitt M.

J Cell Mol Med. 2008 Oct;12(5B):2107-18. doi: 10.1111/j.1582-4934.2008.00234.x. Epub 2008 Jan 11.

31.

[Female patient with organic psychosyndrome and neurological focal signs after immunosuppressant therapy].

Kühnlein P, Ringhoffer M, Tumani H, Gdynia HJ.

Internist (Berl). 2008 Jan;49(1):101-5. German.

PMID:
18060332
32.

RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.

Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F, Yu Y, Götz M, Heyduk M, Ritter G, Speiser DE, Gnjatic S, Guillaume P, Ringhoffer M, Schlenk RF, Liebisch P, Bunjes D, Shiku H, Dohner H, Greiner J.

Blood. 2008 Feb 1;111(3):1357-65. Epub 2007 Oct 31.

33.

Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.

Ringhoffer M, Harsdorf Sv, Schmitt M, Wiesneth M, Zenz T, Stilgenbauer S, Greiner J, Döhner K, Marx M, Döhner H, Bunjes D.

Br J Haematol. 2007 Jan;136(1):127-30.

PMID:
17222200
34.

Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro.

Chen J, Schmitt A, Chen B, Rojewski M, Ringhoffer M, von Harsdorf S, Greiner J, Guillaume P, Döhner H, Bunjes D, Schmitt M.

Cancer Immunol Immunother. 2007 Jun;56(6):849-61. Epub 2006 Sep 29.

PMID:
17009043
35.

[Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway].

Kuefer R, Autenrieth M, Herkommer K, Blum P, Merseburger A, Hofer M, Rinnab L, Gschwend J, Ringhoffer M.

Urologe A. 2006 Mar;45(3):328, 330-5. Review. German.

PMID:
16465522
36.

Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.

Zenz T, Schlenk RF, Glatting G, Neumaier B, Blumstein N, Buchmann I, von Harsdorf S, Ringhoffer M, Wiesneth M, Keller F, Kotzerke J, Röttinger E, Stilgenbauer S, Döhner H, Reske SN, Bunjes D.

J Nucl Med. 2006 Feb;47(2):278-86.

37.

188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.

Ringhoffer M, Blumstein N, Neumaier B, Glatting G, von Harsdorf S, Buchmann I, Wiesneth M, Kotzerke J, Zenz T, Buck AK, Schauwecker P, Stilgenbauer S, Döhner H, Reske SN, Bunjes D.

Br J Haematol. 2005 Aug;130(4):604-13.

PMID:
16098076
38.

Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.

Greiner J, Li L, Ringhoffer M, Barth TF, Giannopoulos K, Guillaume P, Ritter G, Wiesneth M, Döhner H, Schmitt M.

Blood. 2005 Aug 1;106(3):938-45. Epub 2005 Apr 12.

39.

Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.

Li L, Reinhardt P, Schmitt A, Barth TF, Greiner J, Ringhoffer M, Döhner H, Wiesneth M, Schmitt M.

Cancer Immunol Immunother. 2005 Jul;54(7):685-93. Epub 2004 Dec 31.

PMID:
15627212
40.

CD34 cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients.

Ringhoffer M, Wiesneth M, Harsdorf S, Schlenk RF, Schmitt A, Reinhardt PP, Moessner M, Grimminger W, Mertens T, Reske SN, Döhner H, Bunjes D.

Br J Haematol. 2004 Aug;126(4):527-35.

PMID:
15287946
41.

Simultaneous expression of T-cell activating antigens in renal cell carcinoma: implications for specific immunotherapy.

Ringhoffer M, Müller CR, Schenk A, Kirsche H, Schmitt M, Greiner J, Gschwend JE.

J Urol. 2004 Jun;171(6 Pt 1):2456-60.

PMID:
15126875
42.

mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies.

Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, Döhner H, Schmitt M.

Int J Cancer. 2004 Feb 20;108(5):704-11.

43.

Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia.

Li L, Schmitt A, Reinhardt P, Greiner J, Ringhoffer M, Vaida B, Bommer M, Vollmer M, Wiesneth M, Döhner H, Schmitt M.

Cancer Immun. 2003 Jul 16;3:8.

44.

Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia.

Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Döhner H, Schmitt M.

Int J Cancer. 2003 Aug 20;106(2):224-31.

45.

Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia.

Vollmer M, Li L, Schmitt A, Greiner J, Reinhardt P, Ringhoffer M, Wiesneth M, Döhner H, Schmitt M.

Br J Haematol. 2003 Mar;120(6):1000-8.

PMID:
12648070
46.

Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.

Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krähn G, Heilmann V, Gschwend J, Bergmann L, Döhner H, Schmitt M.

Exp Hematol. 2002 Sep;30(9):1029-35.

PMID:
12225794
47.

[Specific cellular immunotherapy of renal cell carcinoma. Current status and prospects].

Ringhoffer M, Gschwend JE.

Urologe A. 2002 May;41(3):249-57. Review. German.

PMID:
12132274
48.

Fatal outcome in a patient developing Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD) without measurable disease.

Ringhoffer M, Döhner K, Scheil S, Wilts H, Mertens T, Grimminger W, Döhner H, Bunjes D.

Bone Marrow Transplant. 2001 Sep;28(6):615-8.

49.

Quantitative assessment of the expression of melanoma-associated antigens by non-competitive reverse transcription polymerase chain reaction.

Ringhoffer M, Schmitt M, Karbach J, Jäger E, Oesch F, Arand M.

Int J Oncol. 2001 Nov;19(5):983-9.

PMID:
11604998
50.

Simultaneous expression of different immunogenic antigens in acute myeloid leukemia.

Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Huebsch S, Maurer U, Bergmann L, Schmitt M.

Exp Hematol. 2000 Dec;28(12):1413-22.

PMID:
11146163

Supplemental Content

Loading ...
Support Center